GOVX
GeoVax Labs, Inc.
There isn't enough reported data to score GOVX yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
GOVX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
GOVX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
GOVX PE Valuation
GOVX has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
GOVX Forward outlook
There aren't enough analyst estimates for GOVX to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
GOVX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$5,728.74 | +$1,741.26 |
| Q2 2024 | -$8,062.74 | -$1,942.74 |
| Q1 2024 | -$8,848.74 | -$3,088.74 |
| Q4 2023 | -$8,716.74 | -$1,246.74 |
| Q3 2023 | -$7,470.00 | +$18,810.00 |
| Q2 2023 | -$6,120.00 | +$21,420.00 |
| Q1 2023 | -$5,760.00 | +$22,050.00 |
| Q4 2022 | -$7,470.00 | +$19,890.00 |
NVO has the stronger earnings trend. Trailing diluted EPS is down 104% for GOVX versus NVO up 4.9%.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
GOVX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $852.3K | +183% |
| Q1 2022 | $81.5K | -26% |
| Q4 2021 | $165K | -34% |
| Q3 2021 | $30.4K | -93% |
| Q2 2021 | $79.7K | -82% |
| Q1 2021 | $110.4K | -85% |
| Q4 2020 | $251.6K | -6.3% |
GOVX's revenue has slid since its 2024 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -636% | +1048 points |
| Q1 2025 | -330% | N/A |
| Q4 2024 | -965% | N/A |
| Q3 2024 | -210% | N/A |
| Q2 2024 | -1684% | N/A |
| Q1 2022 | -2978% | -1562 points |
| Q4 2021 | -8331% | -7800 points |
| Q3 2021 | -6416% | -6311 points |
GOVX's operating margin was −636% last quarter, up 1048 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over GOVX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
GOVX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.3M | +$1.9M |
| Q2 2026 | -$3.7M | +$687K |
| Q1 2026 | -$3.5M | +$2.4M |
| Q4 2025 | -$5M | +$2.8M |
| Q3 2025 | -$6.2M | +$3.1M |
| Q1 2025 | -$6M | -$298.8K |
| Q4 2024 | -$7.8M | +$2.5M |
| Q3 2024 | -$9.3M | -$4.2M |
GOVX has burned cash in almost every quarter: −$16M over the past year, against −$24M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over GOVX on cash generation, producing positive trailing cash flow while its opponent burns cash.
GOVX Net Leverage
GOVX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
GOVX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 1.4 | Oversold |
GOVX's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
GOVX PE vs Healthcare Sector
GOVX has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
GOVX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.42 | 62% below |
| 20 week MA | $12.9 | 84% below |
| 50 week MA | $43.4 | 95% below |
| 100 week MA | $349.0 | 99% below |
| 200 week MA | $1,907.6 | 100% below |
GOVX is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over GOVX on trend strength, trading above more of its moving averages.
GOVX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $143,928.0 | $29,520.0 | -79% |
| 2021 | $29,520.0 | $36,180.0 | +23% |
| 2022 | $36,180.0 | $5,106.5 | -86% |
| 2023 | $5,106.5 | $3,249.1 | -36% |
| 2024 | $3,249.1 | $1,476.0 | -55% |
| 2025 | $1,476.0 | $108.7 | -93% |
| 2026 YTD | $108.7 | $2.04 | -98% |
GOVX has finished four years in a row lower, and it's down 98% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over GOVX on returns for 2026, with the stronger performance.